Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia
- 31 March 2005
- journal article
- case report
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 157 (2) , 104-108
- https://doi.org/10.1016/j.cancergencyto.2004.06.014
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 20 references indexed in Scilit:
- High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemiaBlood, 2004
- The BCR-ABL Story: Bench to Bedside and BackAnnual Review of Immunology, 2004
- Oncogenic interaction between BCR-ABL andNUP98-HOXA9 demonstrated by the use of an in vitro purging culture systemBlood, 2002
- Imatinib Mesylate — A New Oral Targeted TherapyNew England Journal of Medicine, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosome‐positive chronic myelogenous leukaemia with t(7;11)(p15;p15)British Journal of Haematology, 2000
- Erythropoietin and IL-3 Induce Tyrosine Phosphorylation of CrkL and Its Association with Shc, SHP-2, and Cbl in Hematopoietic CellsBiochemical and Biophysical Research Communications, 1997
- A Human Gene (DDX10) Encoding a Putative DEAD-Box RNA Helicase at 11q22–q23Genomics, 1996
- Chromosome banding studies in 106 cases of chronic myelogenous leukemiaJournal of Human Genetics, 1982
- Myeloid Karyotype and the Malignant Phase of Chronic Granulocytic LeukaemiaBritish Journal of Haematology, 1978